-
1
-
-
17644382288
-
Critical evaluation of current treatments in metastatic colorectal cancer
-
Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 2005; 10: 250-261.
-
(2005)
Oncologist
, vol.10
, pp. 250-261
-
-
Venook, A.1
-
2
-
-
0028955388
-
Epidermal growth factor-related peptides and their receptors in human malignancies
-
Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
-
(1995)
Crit Rev Oncol Hematol
, vol.19
, pp. 183-232
-
-
Salomon, D.S.1
Brandt, R.2
Ciardiello, F.3
Normanno, N.4
-
4
-
-
0041629450
-
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
-
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2787-2799
-
-
Mendelsohn, J.1
Baselga, J.2
-
5
-
-
34147130694
-
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents
-
Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007; 5: 203-220.
-
(2007)
Mol Cancer Res
, vol.5
, pp. 203-220
-
-
Tabernero, J.1
-
6
-
-
0037109014
-
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
-
Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-5754.
-
(2002)
Cancer Res
, vol.62
, pp. 5749-5754
-
-
Wakeling, A.E.1
Guy, S.P.2
Woodburn, J.R.3
Ashton, S.E.4
Curry, B.J.5
Barker, A.J.6
Gibson, K.H.7
-
7
-
-
0034068319
-
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
-
Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2053-2063
-
-
Ciardiello, F.1
Caputo, R.2
Bianco, R.3
Damiano, V.4
Pomatico, G.5
de Placido, S.6
Bianco, A.R.7
Tortora, G.8
-
8
-
-
0034489914
-
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
-
Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-4892.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 4885-4892
-
-
Sirotnak, F.M.1
Zakowski, M.F.2
Miller, V.A.3
Scher, H.I.4
Kris, M.G.5
-
9
-
-
0345734200
-
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells
-
Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, Nishio K. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004; 108: 464-472.
-
(2004)
Int J Cancer
, vol.108
, pp. 464-472
-
-
Koizumi, F.1
Kanzawa, F.2
Ueda, Y.3
Koh, Y.4
Tsukiyama, S.5
Taguchi, F.6
Tamura, T.7
Saijo, N.8
Nishio, K.9
-
10
-
-
85047696958
-
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
-
Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86: 1157-1161.
-
(2002)
Br J Cancer
, vol.86
, pp. 1157-1161
-
-
Williams, K.J.1
Telfer, B.A.2
Stratford, I.J.3
Wedge, S.R.4
-
11
-
-
0038599605
-
Initial results of part 2 of a phase I/II pharmacokinetic, pharmacodynamic and biological activity study of ZD1839 ('Iressa'): NCIC CTG IND.122
-
Abs 59
-
Goss GD, Stewart DJ, Hirte H, Miller W, Major P, Batist G, Mathews S, Douglas L, Lorimer I, Seymour L. Initial results of part 2 of a phase I/II pharmacokinetic, pharmacodynamic and biological activity study of ZD1839 ('Iressa'): NCIC CTG IND. 122. Proc Am Soc Clin Oncol 2002; 21: 16 (Abs 59).
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
, pp. 16
-
-
Goss, G.D.1
Stewart, D.J.2
Hirte, H.3
Miller, W.4
Major, P.5
Batist, G.6
Mathews, S.7
Douglas, L.8
Lorimer, I.9
Seymour, L.10
-
12
-
-
33644822287
-
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
-
Rothenberg ML, LaFleur B, Levy DE, Washington MK, Morgan-Meadows SL, Ramanathan RK, Berlin JD, Benson AB 3rd, Coffey RJ. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005; 23: 9265-9274.
-
(2005)
J Clin Oncol
, vol.23
, pp. 9265-9274
-
-
Rothenberg, M.L.1
Lafleur, B.2
Levy, D.E.3
Washington, M.K.4
Morgan-Meadows, S.L.5
Ramanathan, R.K.6
Berlin, J.D.7
Benson 3rd, A.B.8
Coffey, R.J.9
-
13
-
-
34047110824
-
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study
-
Chau I, Cunningham D, Hickish T, Massey A, Higgins L, Osborne R, Botwood N, Swaisland A. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Ann Oncol 2007; 18: 730-737.
-
(2007)
Ann Oncol
, vol.18
, pp. 730-737
-
-
Chau, I.1
Cunningham, D.2
Hickish, T.3
Massey, A.4
Higgins, L.5
Osborne, R.6
Botwood, N.7
Swaisland, A.8
-
14
-
-
43249098618
-
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer
-
Jimeno A, Grávalos C, Escudero P, Sevilla I, Vega-Villegas ME, Alonso V, Juez I, García-Carbonero R, Bovio H, Colomer R, Cortés-Funes H. Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. Clin Transl Oncol 2008; 10: 52-57.
-
(2008)
Clin Transl Oncol
, vol.10
, pp. 52-57
-
-
Jimeno, A.1
Grávalos, C.2
Escudero, P.3
Sevilla, I.4
Vega-Villegas, M.E.5
Alonso, V.6
Juez, I.7
García-Carbonero, R.8
Bovio, H.9
Colomer, R.10
Cortés-Funes, H.11
-
15
-
-
39449139283
-
A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)
-
Stebbing J, Harrison M, Glynne-Jones R, Bridgewater J, Propper D. A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). Br J Cancer 2008; 98: 716-719.
-
(2008)
Br J Cancer
, vol.98
, pp. 716-719
-
-
Stebbing, J.1
Harrison, M.2
Glynne-Jones, R.3
Bridgewater, J.4
Propper, D.5
-
16
-
-
0242442483
-
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas
-
Li B, Chang CM, Yuan M, McKenna WG, Shu HK. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res. 2003; 63: 7443-7450.
-
(2003)
Cancer Res.
, vol.63
, pp. 7443-7450
-
-
Li, B.1
Chang, C.M.2
Yuan, M.3
McKenna, W.G.4
Shu, H.K.5
-
17
-
-
28644451845
-
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells
-
Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 2005; 65: 10524-10535.
-
(2005)
Cancer Res
, vol.65
, pp. 10524-10535
-
-
Kassouf, W.1
Dinney, C.P.2
Brown, G.3
McConkey, D.J.4
Diehl, A.J.5
Bar-Eli, M.6
Adam, L.7
-
18
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
Harris, P.L.7
Haserlat, S.M.8
Supko, J.G.9
Haluska, F.G.10
Louis, D.N.11
Christiani, D.C.12
Settleman, J.13
Haber, D.A.14
-
19
-
-
2342624080
-
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
-
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Jänne, P.A.2
Lee, J.C.3
Tracy, S.4
Greulich, H.5
Gabriel, S.6
Herman, P.7
Kaye, F.J.8
Lindeman, N.9
Boggon, T.J.10
Naoki, K.11
Sasaki, H.12
Fujii, Y.13
Eck, M.J.14
Sellers, W.R.15
Johnson, B.E.16
Meyerson, M.17
-
20
-
-
33750962024
-
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
-
Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-5042.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5034-5042
-
-
Hirsch, F.R.1
Varella-Garcia, M.2
Bunn Jr., P.A.3
Franklin, W.A.4
Dziadziuszko, R.5
Thatcher, N.6
Chang, A.7
Parikh, P.8
Pereira, J.R.9
Ciuleanu, T.10
von Pawel, J.11
Watkins, C.12
Flannery, A.13
Ellison, G.14
Donald, E.15
Knight, L.16
Parums, D.17
Botwood, N.18
Holloway, B.19
-
21
-
-
17844362179
-
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
-
Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286.
-
(2005)
Lancet Oncol
, vol.6
, pp. 279-286
-
-
Moroni, M.1
Veronese, S.2
Benvenuti, S.3
Marrapese, G.4
Sartore-Bianchi, A.5
Di Nicolantonio, F.6
Gambacorta, M.7
Siena, S.8
Bardelli, A.9
-
22
-
-
14644406844
-
Somatic mutations of epidermal growth factor receptor in colorectal carcinoma
-
Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard GF, Ohira M, Hirakawa K, Mori M. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 2005; 11: 1368-1371.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1368-1371
-
-
Nagahara, H.1
Mimori, K.2
Ohta, M.3
Utsunomiya, T.4
Inoue, H.5
Barnard, G.F.6
Ohira, M.7
Hirakawa, K.8
Mori, M.9
-
24
-
-
20444498630
-
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
-
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 643-655
-
-
Cappuzzo, F.1
Hirsch, F.R.2
Rossi, E.3
Bartolini, S.4
Ceresoli, G.L.5
Bemis, L.6
Haney, J.7
Witta, S.8
Danenberg, K.9
Domenichini, I.10
Ludovini, V.11
Magrini, E.12
Gregorc, V.13
Doglioni, C.14
Sidoni, A.15
Tonato, M.16
Franklin, W.A.17
Crino, L.18
Bunn Jr., P.A.19
Varella-Garcia, M.20
more..
-
25
-
-
27144471067
-
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy
-
van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, van Cutsem E, Johnston P. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005; 11: 7480-7489.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7480-7489
-
-
van Schaeybroeck, S.1
Karaiskou-McCaul, A.2
Kelly, D.3
Longley, D.4
Galligan, L.5
van Cutsem, E.6
Johnston, P.7
-
26
-
-
33747886889
-
Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib
-
Cunningham MP, Thomas H, Fan Z, Modjtahedi H. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res 2006; 66: 7708-7715.
-
(2006)
Cancer Res
, vol.66
, pp. 7708-7715
-
-
Cunningham, M.P.1
Thomas, H.2
Fan, Z.3
Modjtahedi, H.4
-
27
-
-
41149169801
-
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry
-
Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K, Keri G, Dominici M, Conte P, Eckhardt S, Kopper L, Schwab R, Petak I. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn 2008; 10: 160-168.
-
(2008)
J Mol Diagn
, vol.10
, pp. 160-168
-
-
Pinter, F.1
Papay, J.2
Almasi, A.3
Sapi, Z.4
Szabo, E.5
Kanya, M.6
Tamasi, A.7
Jori, B.8
Varkondi, E.9
Moldvay, J.10
Szondy, K.11
Keri, G.12
Dominici, M.13
Conte, P.14
Eckhardt, S.15
Kopper, L.16
Schwab, R.17
Petak, I.18
-
28
-
-
33646418681
-
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
-
Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006; 12: 2538-2544.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 2538-2544
-
-
Han, S.W.1
Kim, T.Y.2
Jeon, Y.K.3
Hwang, P.G.4
Im, S.A.5
Lee, K.H.6
Kim, J.H.7
Kim, D.W.8
Heo, D.S.9
Kim, N.K.10
Chung, D.H.11
Bang, Y.J.12
-
29
-
-
19944389532
-
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
-
Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M, Kudoh S. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005; 92: 1711-1719.
-
(2005)
Br J Cancer
, vol.92
, pp. 1711-1719
-
-
Kokubo, Y.1
Gemma, A.2
Noro, R.3
Seike, M.4
Kataoka, K.5
Matsuda, K.6
Okano, T.7
Minegishi, Y.8
Yoshimura, A.9
Shibuya, M.10
Kudoh, S.11
-
30
-
-
8644234228
-
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer
-
Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, Kim TY, Heo DS, Bang YJ, Kim NK. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005; 113: 109-115.
-
(2005)
Int J Cancer
, vol.113
, pp. 109-115
-
-
Han, S.W.1
Hwang, P.G.2
Chung, D.H.3
Kim, D.W.4
Im, S.A.5
Kim, Y.T.6
Kim, T.Y.7
Heo, D.S.8
Bang, Y.J.9
Kim, N.K.10
-
31
-
-
33745727112
-
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
-
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25-38.
-
(2006)
Cancer Cell
, vol.10
, pp. 25-38
-
-
Wang, S.E.1
Narasanna, A.2
Perez-Torres, M.3
Xiang, B.4
Wu, F.Y.5
Yang, S.6
Carpenter, G.7
Gazdar, A.F.8
Muthuswamy, S.K.9
Arteaga, C.L.10
-
32
-
-
29244450494
-
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor
-
Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 2005; 65: 11478-11485.
-
(2005)
Cancer Res
, vol.65
, pp. 11478-11485
-
-
Fujimoto, N.1
Wislez, M.2
Zhang, J.3
Iwanaga, K.4
Dackor, J.5
Hanna, A.E.6
Kalyankrishna, S.7
Cody, D.D.8
Price, R.E.9
Sato, M.10
Shay, J.W.11
Minna, J.D.12
Peyton, M.13
Tang, X.14
Massarelli, E.15
Herbst, R.16
Threadgill, D.W.17
Wistuba, I.I.18
Kurie, J.M.19
-
33
-
-
34249049000
-
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib
-
Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007; 13: 2795-2803.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2795-2803
-
-
Morgillo, F.1
Kim, W.Y.2
Kim, E.S.3
Ciardiello, F.4
Hong, W.K.5
Lee, H.Y.6
-
34
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
-
(2007)
Science
, vol.316
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
Song, Y.4
Hyland, C.5
Park, J.O.6
Lindeman, N.7
Gale, C.M.8
Zhao, X.9
Christensen, J.10
Kosaka, T.11
Holmes, A.J.12
Rogers, A.M.13
Cappuzzo, F.14
Mok, T.15
Lee, C.16
Johnson, B.E.17
Cantley, L.C.18
Jänne, P.A.19
-
35
-
-
0028946604
-
Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer
-
Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S, Plebani M, Gespach C, Comoglio PM. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1: 147-154.
-
(1995)
Clin Cancer Res
, vol.1
, pp. 147-154
-
-
Di Renzo, M.F.1
Olivero, M.2
Giacomini, A.3
Porte, H.4
Chastre, E.5
Mirossay, L.6
Nordlinger, B.7
Bretti, S.8
Bottardi, S.9
Giordano, S.10
Plebani, M.11
Gespach, C.12
Comoglio, P.M.13
-
36
-
-
19544389146
-
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
-
Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225: 1-26.
-
(2005)
Cancer Lett
, vol.225
, pp. 1-26
-
-
Christensen, J.G.1
Burrows, J.2
Salgia, R.3
-
37
-
-
0026504138
-
Characterization of insulinlike growth factor I receptors in human colon cancer
-
Guo YS, Narayan S, Yallampalli C, Singh P. Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology 1992; 102: 1101-1108.
-
(1992)
Gastroenterology
, vol.102
, pp. 1101-1108
-
-
Guo, Y.S.1
Narayan, S.2
Yallampalli, C.3
Singh, P.4
-
38
-
-
0032885494
-
Expression of insulin-like growth factor-1 receptor in human colorectal cancer
-
Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, Karl RC, Coppola D. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-1133.
-
(1999)
Hum Pathol
, vol.30
, pp. 1128-1133
-
-
Hakam, A.1
Yeatman, T.J.2
Lu, L.3
Mora, L.4
Marcet, G.5
Nicosia, S.V.6
Karl, R.C.7
Coppola, D.8
-
39
-
-
0026538194
-
Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha
-
Lahm H, Suardet L, Laurent PL, Fischer JR, Ceyhan A, Givel JC, Odartchenko N. Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. Br J Cancer 1992; 65: 341-346.
-
(1992)
Br J Cancer
, vol.65
, pp. 341-346
-
-
Lahm, H.1
Suardet, L.2
Laurent, P.L.3
Fischer, J.R.4
Ceyhan, A.5
Givel, J.C.6
Odartchenko, N.7
-
40
-
-
10744228945
-
Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway
-
Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ, Coppola D. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 2003; 63: 7708-7716.
-
(2003)
Cancer Res
, vol.63
, pp. 7708-7716
-
-
Sekharam, M.1
Zhao, H.2
Sun, M.3
Fang, Q.4
Zhang, Q.5
Yuan, Z.6
Dan, H.C.7
Boulware, D.8
Cheng, J.Q.9
Coppola, D.10
-
41
-
-
0030909657
-
Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins
-
Párrizas M, Gazit A, Levitzki A, Wertheimer E, LeRoith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997; 138: 1427-1433.
-
(1997)
Endocrinology
, vol.138
, pp. 1427-1433
-
-
Párrizas, M.1
Gazit, A.2
Levitzki, A.3
Wertheimer, E.4
Leroith, D.5
-
42
-
-
33846889291
-
Growth factor receptor interplay and resistance in cancer
-
Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 2006; 13 Suppl 1: S45-S51.
-
(2006)
Endocr Relat Cancer
, vol.13
, Issue.SUPPL. 1
-
-
Jones, H.E.1
Gee, J.M.2
Hutcheson, I.R.3
Knowlden, J.M.4
Barrow, D.5
Nicholson, R.I.6
-
43
-
-
0037383322
-
GSK-3: tricks of the trade for a multi-tasking kinase
-
Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-1186.
-
(2003)
J Cell Sci
, vol.116
, pp. 1175-1186
-
-
Doble, B.W.1
Woodgett, J.R.2
-
44
-
-
0442276554
-
The glamour and gloom of glycogen synthase kinase-3
-
Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29: 95-102.
-
(2004)
Trends Biochem Sci
, vol.29
, pp. 95-102
-
-
Jope, R.S.1
Johnson, G.V.2
-
45
-
-
0028840004
-
Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells
-
Eldar-Finkelman H, Seger R, Vandenheede JR, Krebs EG. Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. J Biol Chem 1995; 270: 987-990.
-
(1995)
J Biol Chem
, vol.270
, pp. 987-990
-
-
Eldar-Finkelman, H.1
Seger, R.2
Vandenheede, J.R.3
Krebs, E.G.4
-
46
-
-
0037155824
-
Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation
-
Rössig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S. Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J Biol Chem 2002; 277: 9684-9689.
-
(2002)
J Biol Chem
, vol.277
, pp. 9684-9689
-
-
Rössig, L.1
Badorff, C.2
Holzmann, Y.3
Zeiher, A.M.4
Dimmeler, S.5
-
47
-
-
0029776032
-
A molecular mechanism for the effect of lithium on development
-
Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 8455-8459
-
-
Klein, P.S.1
Melton, D.A.2
-
48
-
-
0028176021
-
Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation
-
Wang QM, Fiol CJ, DePaoli-Roach AA, Roach PJ. Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem 1994; 269: 14566-14574.
-
(1994)
J Biol Chem
, vol.269
, pp. 14566-14574
-
-
Wang, Q.M.1
Fiol, C.J.2
Depaoli-Roach, A.A.3
Roach, P.J.4
-
49
-
-
0020315756
-
The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor
-
Massagué J, Czech MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem 1982; 257: 5038-5045.
-
(1982)
J Biol Chem
, vol.257
, pp. 5038-5045
-
-
Massagué, J.1
Czech, M.P.2
-
50
-
-
0026674185
-
Insulin-like growth factor I receptor gene structure
-
Abbott AM, Bueno R, Pedrini MT, Murray JM, Smith RJ. Insulin-like growth factor I receptor gene structure. J Biol Chem 1992; 267: 10759-10763.
-
(1992)
J Biol Chem
, vol.267
, pp. 10759-10763
-
-
Abbott, A.M.1
Bueno, R.2
Pedrini, M.T.3
Murray, J.M.4
Smith, R.J.5
-
51
-
-
0036793827
-
Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer
-
Reinmuth N, Liu W, Fan F, Jung YD, Ahmad SA, Stoeltzing O, Bucana CD, Radinsky R, Ellis LM. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002; 8: 3259-3269.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3259-3269
-
-
Reinmuth, N.1
Liu, W.2
Fan, F.3
Jung, Y.D.4
Ahmad, S.A.5
Stoeltzing, O.6
Bucana, C.D.7
Radinsky, R.8
Ellis, L.M.9
-
52
-
-
0031789137
-
Deficient processing and activity of type I insulin-like growth factor receptor in the furin-deficient LoVo-C5 cells
-
Lehmann M, André F, Bellan C, Remacle-Bonnet M, Garrouste F, Parat F, Lissitsky JC, Marvaldi J, Pommier G. Deficient processing and activity of type I insulin-like growth factor receptor in the furin-deficient LoVo-C5 cells. Endocrinology 1998; 139: 3763-3771.
-
(1998)
Endocrinology
, vol.139
, pp. 3763-3771
-
-
Lehmann, M.1
André, F.2
Bellan, C.3
Remacle-Bonnet, M.4
Garrouste, F.5
Parat, F.6
Lissitsky, J.C.7
Marvaldi, J.8
Pommier, G.9
-
53
-
-
19944427176
-
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
-
Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11: 793-814.
-
(2004)
Endocr Relat Cancer
, vol.11
, pp. 793-814
-
-
Jones, H.E.1
Goddard, L.2
Gee, J.M.3
Hiscox, S.4
Rubini, M.5
Barrow, D.6
Knowlden, J.M.7
Williams, S.8
Wakeling, A.E.9
Nicholson, R.I.10
-
54
-
-
0031034574
-
Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
-
Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17: 1595-1606.
-
(1997)
Mol Cell Biol
, vol.17
, pp. 1595-1606
-
-
Kulik, G.1
Klippel, A.2
Weber, M.J.3
-
55
-
-
0036141447
-
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling
-
Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62: 200-207.
-
(2002)
Cancer Res
, vol.62
, pp. 200-207
-
-
Chakravarti, A.1
Loeffler, J.S.2
Dyson, N.J.3
-
56
-
-
0345826131
-
The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase
-
Ahmad T, Farnie G, Bundred NJ, Anderson NG. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem 2004; 279: 1713-1719.
-
(2004)
J Biol Chem
, vol.279
, pp. 1713-1719
-
-
Ahmad, T.1
Farnie, G.2
Bundred, N.J.3
Anderson, N.G.4
-
57
-
-
0035477020
-
GSK3 takes centre stage more than 20 years after its discovery
-
Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359: 1-16.
-
(2001)
Biochem J
, vol.359
, pp. 1-16
-
-
Frame, S.1
Cohen, P.2
-
58
-
-
33749076514
-
Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells
-
Wang Q, Zhou Y, Evers BM. Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells. Neoplasia 2006; 8: 781-787.
-
(2006)
Neoplasia
, vol.8
, pp. 781-787
-
-
Wang, Q.1
Zhou, Y.2
Evers, B.M.3
-
59
-
-
2342549202
-
Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity
-
Turenne GA, Price BD. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. BMC Cell Biol 2001; 2: 12.
-
(2001)
BMC Cell Biol
, vol.2
, pp. 12
-
-
Turenne, G.A.1
Price, B.D.2
-
60
-
-
0035413614
-
Glycogen synthase kinase-3: properties, functions, and regulation
-
Ali A, Hoeflich KP, Woodgett JR. Glycogen synthase kinase-3: properties, functions, and regulation. Chem Rev 2001; 101: 2527-2540.
-
(2001)
Chem Rev
, vol.101
, pp. 2527-2540
-
-
Ali, A.1
Hoeflich, K.P.2
Woodgett, J.R.3
-
61
-
-
9644281593
-
Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway
-
Yamaguchi K, Lee SH, Eling TE, Baek SJ. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem 2004; 279: 49617-49623.
-
(2004)
J Biol Chem
, vol.279
, pp. 49617-49623
-
-
Yamaguchi, K.1
Lee, S.H.2
Eling, T.E.3
Baek, S.J.4
-
62
-
-
0033564697
-
CDK inhibitors: positive and negative regulators of G1-phase progression
-
Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
-
(1999)
Genes Dev
, vol.13
, pp. 1501-1512
-
-
Sherr, C.J.1
Roberts, J.M.2
|